The Clinical Trials on Alzheimer's Disease Conference (CTAD) includes a focus on Alzheimer disease (AD) therapeutic trials, featuring leaders in AD research from industry and academia with an aim of forming partnerships to progress the development of effective treatments to fight the disease.
Understanding Clinical Predictors of Response to Nabilone in Alzheimer Agitation
December 10th 2024Krista L. Lanctôt, PhD, professor of psychiatry and pharmacology at the University of Toronto, talked about findings from a recent post hoc analysis presented at CTAD 2024 on nabilone for agitation in Alzheimer disease.
Collaboration and Innovation in Alzheimer Disease Clinical Trial Research: Howard Fillit, MD
November 26th 2024The cofounder and chief science officer of the Alzheimer's Drug Discovery Foundation highlighted the critical role of collaboration and innovative diagnostics for advancing Alzheimer disease care. [WATCH TIME: 4 minutes]
Redesigning Clinical Trials in Alzheimer Disease to Promote Diversity and Accessibility
November 23rd 2024Jessica Langbaum, PhD, the senior director of research strategy at Banner Alzheimer’s Institute, discussed the challenges and opportunities in improving diversity in Alzheimer disease clinical trials.
Exploring Blood-Based Biomarkers and Treatment Eligibility in Alzheimer Disease: Gil Rabinovici, MD
November 21st 2024The professor of neurology and radiology at University of California, San Francisco, discussed the potential of blood-based biomarkers in Alzheimer treatment eligibility, highlighting current limitations and the importance of safety monitoring. [WATCH TIME: 7 minutes]
Guidance on Safe Use of Donanemab for Alzheimer Disease in Clinical Settings: Gil Rabinovici, MD
November 12th 2024The professor of neurology and radiology at University of California, San Francisco talked about how the new appropriate use recommendations of donanemab aims to safely integrate this anti-amyloid antibody into the clinical practice. [WATCH TIME: 7 minutes]
Early Clinical Use of Anti-Amyloid Therapy for Alzheimer Disease in Japan: Takeshi Iwatsubo, MD, PhD
November 8th 2024The professor of neuropathology at the University of Tokyo School of Medicine talked about the latest data on lecanemab use in clinical practice for Alzheimer disease in Japan presented at CTAD 2024. [WATCH TIME: 4 minutes]
Acumen Pharmaceuticals’ Phase 2 Advancements in Alzheimer Disease Screening: Todd Feaster, PsyD
November 1st 2024The senior clinical research scientist at Acumen Pharmaceuticals talked about the company's approach to refining Alzheimer screening by implementing plasma p-tau 217 biomarkers. [WATCH TIME: 5 minutes]